Vrati se na sadržaj

Pređi na pomoćni meni

Jehovini svedoci

srpski (latinica)

Beta talasemija (pedijatrija)

Beta talasemija major — farmakološka indukcija sinteze fetalnog hemoglobina

Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Izvor‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indeks‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

http://www.ncbi.nlm.nih.gov/pubmed/21602718

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Izvor‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indeks‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

http://www.ncbi.nlm.nih.gov/pubmed/23389500

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Izvor‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indeks‎: PubMed 17984691

http://www.ncbi.nlm.nih.gov/pubmed/17984691

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Izvor‎: Blood 2003;102(4):1529-30.

Indeks‎: PubMed 12702505

http://www.ncbi.nlm.nih.gov/pubmed/12702505

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Izvor‎: Transfusion 2007;47(10):1830-6.

Indeks‎: PubMed 17880608

http://www.ncbi.nlm.nih.gov/pubmed/17880608

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia.

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Izvor‎: Iran J Blood Cancer 2009;1(4):147-50.

Indeks‎: IMEMR 107228

http://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Izvor‎: Int J Hematol 2012;95(1):51-6.

Indeks‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

http://www.ncbi.nlm.nih.gov/pubmed/22180324

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ߺ thalassemia.

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Izvor‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indeks‎: PubMed 12468925

http://www.ncbi.nlm.nih.gov/pubmed/12468925

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin.

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Izvor‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indeks‎: PubMed 9185215

http://www.ncbi.nlm.nih.gov/pubmed/9185215

Fetal globin gene inducers: novel agents and new potential.

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Izvor‎: Ann N Y Acad Sci 2010;1202:158-64.

Indeks‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

http://www.ncbi.nlm.nih.gov/pubmed/20712788

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Izvor‎: Haematologica 2004;89(10):1172-8.

Indeks‎: PubMed 15477200

http://www.ncbi.nlm.nih.gov/pubmed/15477200

Hydroxyurea therapy in 49 patients with major beta-thalassemia.

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Izvor‎: Arch Iran Med 2009;12(3):295-7.

Indeks‎: PubMed 19400608

http://www.ncbi.nlm.nih.gov/pubmed/19400608


Deo s medicinskim informacijama na sajtu jw.org namenjen je prvenstveno lekarima specijalistima i drugim zdravstvenim radnicima. On ne sadrži medicinske savete niti preporuke za određeno lečenje i nije zamena za konsultovanje sa stručnim zdravstvenim radnikom. Medicinsku literaturu koja se ovde navodi nisu izdali Jehovini svedoci, ali u njoj se govori o strategijama beskrvnog lečenja koje se mogu uzeti u obzir. Svaki medicinski radnik je odgovoran da bude u toku s novim informacijama, razmotri više načina za pružanje medicinske nege i da pomogne pacijentima da donesu odluku koja je u skladu s njihovim medicinskim stanjem, željama, merilima i verovanjima. Nisu sve ovde navedene strategije primenjive i prihvatljive za sve pacijente.

Za pacijente: Uvek se konsultujte s vašim lekarom ili drugim kvalifikovanim zdravstvenim radnikom u vezi s vašim medicinskim stanjem i lečenjem. Ako smatrate da imate zdravstvenih problema, obratite se lekaru.

Korišćenje ovog veb-sajta propisano je pravilima korišćenja.